Doxycycline in Treatment of Bleeding With Depot Medroxyprogesterone Acetate (DMPA) (DOX-DMPA)

This study has been completed.
Information provided by (Responsible Party):
Omar Mamdouh Shaaban, Assiut University Identifier:
First received: December 6, 2010
Last updated: November 25, 2011
Last verified: November 2011
This study aims to test the effect of Doxycycline in treatment of uterine bleeding during the use of injectable contraception that contains one hormone "progesterone only".

Condition Intervention Phase
Uterine Hemorrhage
Drug: Doxycycline
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Doxycycline in Treatment of Bleeding With DMPA: a Double Blinded Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Assiut University:

Primary Outcome Measures:
  • Stoppage of bleeding within 7 days [ Time Frame: 7 days from starting of tretment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of days needed to stop a current attack of bleeding [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Next bleeding free interval [ Time Frame: 3 month ] [ Designated as safety issue: No ]
  • Uterine bleeding patterns in the next 3 months after treatment [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Women satisfaction with the treatment she received [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Side effects encountered during treatment [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
  • Discontinuation of the DMPA and its reason [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 68
Study Start Date: January 2008
Study Completion Date: January 2011
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Women in this arm will receive identical Placebo capsules twice daily for 5 days
Drug: Placebo
Placebo capsules twice daily for 5 days
Active Comparator: Doxycycline
Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
Drug: Doxycycline
100 mg Doxycycline capsules twice daily for 5 days


Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women under DMPA contraception for at least one month.
  2. Accept to participate in the trial after receiving adequate information about the trial including information that she is a part of randomization comprising the possibility of receiving new treatment for bleeding or inactive ingredients.
  3. Women's ability to keep an accurate menstrual diary for the study.

Exclusion Criteria:

  1. Lactating women for the fear of the effect of tetracycline on the breast-fed infant.
  2. Patients with already diagnosed local gynecological abnormality.
  3. Women receiving treatment for bleeding within the last one month.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01254799

Faculty of Medicine
Assiut, Egypt
Sponsors and Collaborators
Omar Mamdouh Shaaban
Principal Investigator: Hany Abdel-Aleem, MD Assiut University
Study Director: Omar M Shaaban, MD Assiut University
Study Chair: Mahmoud Abdel=Aleem, MD Assiut University
Study Chair: Gehian N Fetih, PH.D Faculty of Pharmacy, Assiut University
  More Information

Responsible Party: Omar Mamdouh Shaaban, Dr, Assiut University Identifier: NCT01254799     History of Changes
Other Study ID Numbers: DOX-DMPA 
Study First Received: December 6, 2010
Last Updated: November 25, 2011
Health Authority: Egypt: Institutional Review Board

Additional relevant MeSH terms:
Uterine Hemorrhage
Genital Diseases, Female
Pathologic Processes
Uterine Diseases
Medroxyprogesterone Acetate
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antiparasitic Agents
Antiprotozoal Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Physiological Effects of Drugs
Reproductive Control Agents processed this record on May 24, 2016